

The Lilly Phenotypic Drug Discovery Initiative



Connecting Compounds to Patients


Lilly will provide **no-cost** access to phenotypic assay panel for external investigators

PD² panel includes disease-relevant assays

Confidential compound submission via web-based interface

Full data report provided to investigator

Promising findings can serve as basis for a collaboration agreement



PD²
Phenotypic Drug Discovery

Lilly
Answers That Matter.

Benefits of PD²

An Opportunity for Open Innovation



Access to increased molecular diversity for phenotypic disease models.

Ability to identify and establish potential collaborations.

Bring forward innovation.

External Investigator and/or Institution

Access to highly relevant assay modules and publication quality biological data to test hypotheses.

Establish possible collaboration with Lilly. Increased access to resources.

Advance laboratory science

Lilly's PD² initiative was established through a close partnership with AUTM® (Association of University Technology Managers)

The PD² Screening Panel

The PD² screening panel is currently comprised of five modules which are relevant to therapeutic areas of long-term strategic interest to Lilly, including oncology, neurological disorders, and metabolic diseases. This panel may change over time to reflect additional research interests.

Each assay module is composed of a primary phenotypic screening assay, followed by relevant secondary biochemical and cellular follow-up assays that further define the compound's activity profile and early potential for additional optimization. (see diagram lower right)

Current Phenotypic Assay Modules

Alzheimer's Disease

– ApoE Secretion

Cancer

– Cell Cycle G2/M Arrest

Cancer


– Anti-Angiogenesis

Diabetes


– Insulin Secretion

Bone Formation

– Wnt Pathway



How Does PD² Work



The PD² Website

The PD² website provides additional detailed information and allows the confidential submission of structures for assessing interest for screening by Lilly, and if accepted, facilitates the shipment of compounds and retrieval of biological data reports.



How do I know my information is secure?

PD² uses data encryption and a dedicated server located in a secure area to ensure that all data submitted by investigators remains secure. Lilly and Lilly vendors do not have access to compound information until such time as a collaboration agreement is made with Lilly and such information is provided by the investigator.

pd2.lilly.com
(available in mid 2009)

Who Can Participate in PD²?

Participation is limited to institutions who are research universities, institutes, and biotech.

What kind of molecules can I submit?

The target compounds sought for screening include small molecules, natural products and natural product derivatives. At this time we will not be accepting proteins, peptides, antisense oligonucleotides and RNAi's.

How can I become affiliated with PD²?

Any Institution that wishes to become a member of PD² can download a Material Transfer Agreement (MTA) from the PD² website and then sign and submit this MTA to Lilly. This process allows institutions to join and become members of the program by signing this one-size-fits-all document. Lilly's posting of the MTA to the PD² website constitutes a tacit agreement and serves as a Lilly's signature.

How was the MTA generated? Was there external input or feedback during the drafting of this document?

The MTA was written by Lilly's attorneys and incorporates feedback from pilot participant institutions. It was reviewed by AUTM® consultants.

For additional details please visit the website at **pd2.lilly.com** (avail. mid 2009)

If you wish to participate and need additional information, please email **pd2@lilly.com** with the subject line of "PD2: Interested in Participating".

Lilly
Answers That Matter.